The Promise of Scientific Partnerships with People on the Spectrum
The Promise of Scientific Partnerships with People on the Spectrum
Five collaborations involving autistic scientists and experts are advancing autism research, from lending support for theories of the condition to shoring up trials of new treatments.
The Promise of Scientific Partnerships with People on the Spectrum
The Promise of Scientific Partnerships with People on the Spectrum

Five collaborations involving autistic scientists and experts are advancing autism research, from lending support for theories of the condition to shoring up trials of new treatments.

Five collaborations involving autistic scientists and experts are advancing autism research, from lending support for theories of the condition to shoring up trials of new treatments.

drug development
UK Approves Arthritis Drugs for Critically Ill COVID-19 Patients
UK Approves Arthritis Drugs for Critically Ill COVID-19 Patients
Asher Jones | Jan 11, 2021
The immunosuppressive drugs tocilizumab and sarilumab improved survival and recovery time of intensive care COVID-19 patients, according to a preprint.
What’s Ahead for SARS-CoV-2 Research in 2021
What’s Ahead for SARS-CoV-2 Research in 2021
Shawna Williams | Jan 8, 2021
From new treatments to an investigation into the virus’s origins, here are some of the developments we can expect this year.
Promoting Effective Project Teams for Drug Discovery
Promoting Effective Project Teams for Drug Discovery
The Scientist Creative Services Team | Dec 30, 2020
Download this white paper from Collaborative Drug Discovery to explore how modern informatics systems like CDD Vault® can provide a cross-domain platform for storage, analysis, and sharing to promote greater collaboration between drug discovery project team members.
RNA Interference Comes of Age
RNA Interference Comes of Age
Diana Kwon | Dec 9, 2020
The third FDA approval of an RNAi-based therapeutic marks the growing success of a technique that took two decades to get off the ground.
Opinion: Emergency Use Authorizations Are a Threat to Science<strong>&nbsp;</strong>
Opinion: Emergency Use Authorizations Are a Threat to Science 
Kevin J. Tracey, Christina Brennan | Dec 1, 2020
As COVID-19 therapies get emergency-use green lights, the Biden administration must organize a therapeutic review board to help identify what’s working and what’s not.
Pharma Looks to Outer Space to Boost Drug R&amp;D
Pharma Looks to Outer Space to Boost Drug R&D
Katarina Zimmer | Dec 1, 2020
There are benefits of studying certain biological processes under microgravity, but whether those advantages outweigh the costs of getting experiments off Earth remains to be seen.
Concerns over Efficacy and Cost of Muscle Wasting Treatments
Concerns over Efficacy and Cost of Muscle Wasting Treatments
Ruth Williams | Nov 11, 2020
Two new medications for treating a rare and deadly neuromuscular disease have high prices and questionable efficacies, say scientists.
Scientists Probe Blockers for the Coronavirus Spike Protein
Scientists Probe Blockers for the Coronavirus Spike Protein
Anthony King | Nov 5, 2020
SARS-CoV-2, the virus that causes COVID-19, taps into human proteases such as furin to enter cells. Temporarily inhibiting those enzymes might stymie infection.
Infographic: How Vaccines Train Innate Immunity
Infographic: How Vaccines Train Innate Immunity
Shawna Williams | Nov 1, 2020
A recent study elucidates some of the changes that occur in the body after inoculation with a tuberculosis vaccine.